← All trials
NCT04014803
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 8, 2019
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 3500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sungkyunkwan UniversityLead sponsor
- Gachon UniversityCollaborator
- Chonbuk National UniversityCollaborator
- Yeungnam UniversityCollaborator
- Chungnam National UniversityCollaborator
- Chung-Ang UniversityCollaborator
- Sungkyunkwan UniversityStudy chair
- Sungkyunkwan UniversityReponsible party - principal investigator
- Catholic University of KoreaCollaborator
- Keimyung UniversityCollaborator
- Inje UniversityCollaborator
- Dankook UniversityCollaborator
- Chonnam National UniversityCollaborator
- Wonkwang UniversityCollaborator
- Incheon St.Mary's HospitalCollaborator
- Soonchunhyang UniversityCollaborator
- Gyeongsang UniversityCollaborator
- Ewha Womans UniversityCollaborator
- Wonju Christian HospitalCollaborator
- Sejong General HospitalCollaborator
- Konkuk UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.